Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 65% of modeled bridge. Strengths: Commercial Payer %, Bed Count. Risks: Occupancy Rate, Net-to-Gross Ratio. Risk-adjusted uplift: $0.5M (vs $0.8M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $293K | $293K | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $282K | $8K | $290K | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $45K | $133K | $178K | $561K | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $10K | $10K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 72.8% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $73K | $146K | $219K | $293K | $293K | $293K | $293K |
| Denial Rate Reduction | $0 | $72K | $145K | $217K | $290K | $290K | $290K | $290K |
| A/R Days Reduction | $0 | $59K | $119K | $178K | $178K | $178K | $178K | $178K |
| Clean Claim Rate | $0 | $5K | $10K | $10K | $10K | $10K | $10K | $10K |
| Cumulative | $0 | $210K | $420K | $624K | $770K | $770K | $770K | $770K |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $770K is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 129% / 63.1x | 134% / 70.4x | 139% / 77.8x | 141% / 81.5x | 143% / 85.2x |
| 9.0x | 123% / 55.7x | 128% / 62.2x | 133% / 68.8x | 135% / 72.1x | 137% / 75.3x |
| 10.0x | 118% / 49.8x | 123% / 55.7x | 128% / 61.6x | 130% / 64.5x | 132% / 67.5x |
| 11.0x | 114% / 45.0x | 119% / 50.3x | 123% / 55.7x | 126% / 58.4x | 128% / 61.1x |
| 12.0x | 110% / 41.0x | 115% / 45.9x | 119% / 50.8x | 121% / 53.2x | 123% / 55.7x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 85% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 0.9x, adding 7.5 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $97K | — | $97K | 0.7% |
| Year 1 | $100K | +$513K | $614K | 4.2% |
| Year 2 | $103K | +$770K | $873K | 6.0% |
| Year 3 | $106K | +$770K | $876K | 6.0% |
| Year 4 | $110K | +$770K | $880K | 6.0% |
| Year 5 | $113K | +$770K | $883K | 6.0% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $146K | $219K | $293K | $351K |
| Denial Rate Reductio | $145K | $217K | $290K | $348K |
| A/R Days Reduction | $89K | $134K | $178K | $214K |
| Clean Claim Rate | $5K | $7K | $10K | $12K |
| Total | $385K | $578K | $770K | $924K |
Peer Context — Where This Hospital Sits
Key metrics vs 383 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 0.7% | -25.3% | -9.5% | 3.1% | P70 |
| Net-to-Gross | 69.7% | 40.5% | 59.1% | 72.8% | P70 |
| Occupancy | 30.1% | 15.8% | 26.3% | 42.3% | P59 |
| Rev/Bed | $1.8M | $751K | $1.3M | $2.1M | P69 |
| Exp/Bed | $1.8M | $886K | $1.4M | $2.3M | P64 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.